白云山附属拟参与设立广药广开基金和广药荔湾基金

Core Viewpoint - The company has approved investments through its subsidiary, which will enhance its presence in the biopharmaceutical sector and support its transition towards a technology-driven development model [1] Group 1: Investment Agreements - The board approved a partnership agreement involving the establishment of the Guangyao Guangkai Fund, with contributions of RMB 97.5 million from Guangyao Phase II Fund, RMB 2.5 million from Guangyao Capital, and RMB 100 million from Guangkai Fund [1] - Another partnership agreement was approved for the establishment of the Guangyao Liwan Fund, with contributions of RMB 99.5 million from Guangyao Phase II Fund, RMB 3.5 million from Guangyao Capital, RMB 98.5 million from Angel Mother Fund, and RMB 98.5 million from Liwan Industrial Investment Fund [1] Group 2: Strategic Objectives - The investments align with the Guangyao Phase II Fund's investment direction, aiming to expand its investment scale, diversify risks, and accelerate investment pace and efficiency [1] - The company intends to strengthen its layout in innovative drugs, modern traditional Chinese medicine, and high-end medical devices, focusing on early-stage investments in quality enterprises to foster potential companies [1] - This strategy is designed to facilitate technological upgrades and value chain extensions, laying a solid foundation for high-quality development [1]